RENOVARO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.97 USD | +5.75% |
|
-14.16% | -69.40% |
| Apr. 24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
| Apr. 18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M |
|---|---|---|---|---|---|
| Net income 2022 | -113M | Net income 2023 | -39M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M | Net Debt 2023 | 3.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.45% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +5.75% | ||
| 1 week | -14.16% | ||
| Current month | -38.61% | ||
| 1 month | -55.30% | ||
| 3 months | -57.27% | ||
| 6 months | -66.78% | ||
| Current year | -69.40% |
1 week
0.82
1.17
1 month
0.822.20
Current year
0.825.25
1 year
0.395.25
3 years
0.3913.78
5 years
0.3913.78
10 years
0.3913.78
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 18-01-22 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-20 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 19-12-31 |
Avram Miller
BRD | Director/Board Member | - | 23-10-10 |
James Sapirstein
BRD | Director/Board Member | 63 | 18-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 17 M€ | +5.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.97 | +5.75% | 153,451 |
| 24-05-16 | 0.9173 | -3.17% | 359,583 |
| 24-05-15 | 0.9473 | -8.91% | 237,061 |
| 24-05-14 | 1.04 | -10.34% | 258,894 |
| 24-05-13 | 1.16 | +2.65% | 236,060 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -69.40% | 139M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.74% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- RENB Stock
